Methods and compositions for immune protection against extra-intestinal pathogenic E. coli

Abstract

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonasaeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62 / 209,091, filed August 24, 2015, and U.S. Provisional Patent Application No. 62 / 210,655, filed August 27, 2015 , the disclosure of which is incorporated herein by reference in its entirety. field of invention [0003] The present invention relates to be used for inducing to enteropathogenic escherichia coli ( Escherichia coli ) (ExPEC) immune response compositions and methods, thereby providing immune protection against diseases associated with ExPEC. In particular, embodiments of the present invention relate to multivalent vaccines containing each and Pseudomonas aeruginosa ( Pseudomonas aeruginosa ) Conjugates of Escherichia coli polysaccharide antigens O25B, O1A, O2 and O6A covalently bound to detoxified exotoxin A of the carrier protein. Background of the invention [0004] Extraenteric pathogenic Escherichia ...

AI Technical Summary

Problems solved by technology

Despite the overrepresentation of certain serotypes in ExPEC infection, surface polysaccharides from ExPEC isolates display considerable antigenic diversity, making the development of surface polysaccharide-based ExPEC vaccines extremely challenging (Russo et al. People, Vaccine. 2007; 25: 3859-3870)

Also, some O-antigens may be weakly immunogenic

Furthermore, based on studies from pneumococcal conjugate vaccines, when many serotypes can cause disease, vaccine composition such as the choice of serotypes to be included in the vaccine and the dose level of the included serotypes may be critical , because the use of vaccines against certain serotypes could potentially increase carriage and disease from serotypes not included in the vaccine, or even included in the vaccine but only weakly effective in immunity against serotypes (Lipsitch, Emerging Infectious Diseases; 1999, 5:336-345)

Images